GVHD

December 5, 2019December 10, 2019

Orencia Given FDA’s Breakthrough Status as Treatment to Prevent Graft-versus-Host Disease After Stem Cell Transplant

News

Bristol-Myers Squibb‘s arthritis medicine Orencia (abatacept) has been named Breakthrough Therapy by the U.S. Food and Drug Administration for the prevention of acute graft-versus-host disease (GvHD) in patients who received ... Read more

May 7, 2018

Arthritis Medication May Prevent GvHD, Side Effect of Stem Cell Transplants, Mouse Study Suggests

News

Baricitinib, a medicine approved in Europe for the treatment for rheumatoid arthritis, both prevented and reverted a life-threatening complication of stem cell transplants called graft-versus-host disease, a study in mice suggests. Notably, ... Read more

December 12, 2017December 12, 2017

Immune Response to Reactive Herpes Virus Tied to Graft-versus-host Disease in Transplant Patients in Study

News

The immune system’s response to reactivated human cytomegalovirus (hCMV) infection, a form of herpes virus, has been linked to the onset of graft-versus-host disease (GVHD). The discovery, made by a ... Read more

September 27, 2017September 27, 2017

Phase 2 PROTECT Trial Evaluates ProTmune for Prevention of Acute Graft-Versus-Host Disease

News

Fate Therapeutics has initiated enrollment in the Phase 2 stage of PROTECT, a combined, open-label Phase 1/2 clinical trial evaluating ProTmune for the prevention of acute graft-versus-host disease (GvHD) in ... Read more

June 1, 2017June 1, 2017

Kiadis Hosts NYC Meeting to Discuss Candidate Therapy ATIR101, Risks of Haploidentical HSCT in Blood Cancer

News

Kiadis Pharma hosted a May 31 lunch meeting in New York to analyze the risks and benefits of haploidentical hematopoietic stem cell transplants (HSCT) in treating blood cancers. Two experts, Dr. Stephen ... Read more

April 21, 2017

Manipulating Select T-cells May Prevent Dangerous Side Effect of Stem Cell Therapy

News

Controlling the balance of two subsets of immune T-cells, known as CD4+ and CD8+, after stem cell transplants makes it possible to prevent graft-versus-host disease (GVHD) while keeping the anti-cancer ... Read more

August 19, 2016August 19, 2016

T-cell Lymphoma/Leukemia Patients Eligible for HSCT Cautioned on Use of Poteligeo

News

Patients with adult T-cell leukemia/lymphoma (ATLL) who were treated with Poteligeo (mogamulizumab), an anti-CCR4 monoclonal antibody, may be at higher risk for serious graft-versus-host disease (GvHD)-related complications following allogeneic hematopoietic stem ... Read more

August 17, 2016August 17, 2016

Side Effects of Bone Marrow Transplant Reduced by Expanding Regulatory T-Cells in Mouse Study

News

Researchers at the University Hospital Würzburg in Germany have come up with a new approach that prevents graft-versus-host disease (GvHD) from developing in animal models of bone marrow transplants. The study, “Exogenous ... Read more

August 9, 2016August 9, 2016

Bellicum’s T-Cell Therapy, Graft-Versus-Host Disease Activator Receive European Orphan Drug Designations

News

Bellicum Pharmaceuticals has announced that two of its lead product candidates, BPX-501 and rimiducid, have been granted orphan drug designations by the European Commission’s (EC) drug regulatory agency. Bellicum says it ... Read more

July 18, 2016July 18, 2016

Blood Cancer Patients Who Relapsed After Stem-Cell Transplant May Benefit from Immunotherapy

News

Patients with advanced hematologic cancers who relapse following allogenic hematopoietic stem cell transplantation (HSCT) have a very poor prognosis. Now, researchers at the Dana-Farber Cancer Institute have shown that the outcome ... Read more